Given these compelling results, Creative Medical Technology plans to advance the development of AlloStem (CELZ-201) for the treatment of late-stage Type 2 Diabetes and explore other potential ...

Creative Medical Technology (CELZ) announced one-year follow-up data from the AlloStem Type 2 Diabetes pilot study for late-stage patients.

PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative ...

Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology firm specializing in regenerative medicine with a market capitalization of approximately $7 million, has revealed promising one-year follow-up ...

PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine ...

PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company ...

We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to ...

(RTTNews) - Creative Medical Technology Holdings, Inc. (CELZ), a clinical-stage biotechnology company, has expanded its partnership with Greenstone Biosciences Inc. to enhance the development of ...

PHOENIX - Creative Medical (TASE:PMCN) Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology firm, has announced a strategic collaboration with Greenstone Biosciences Inc. to utilize ...

PHOENIX - Creative Medical (TASE:PMCN) Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology firm, has announced a strategic collaboration with Greenstone Biosciences Inc. to ...

In this article, we are going to take a look at where Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) stands against other AI news and ratings investors are keeping their eye on.